Clinical Trial Update: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pegylated interferon alfa-2a as salvage therapy in high-risk polycythemia vera or high-risk essential thrombocythemia; the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Ronald Hoffman | Conditions: High Risk Polycythemia Vera, High Risk Essential Thrombocythemia | Phase 2 | Status: COMPLETED